The lead indications for anticoagulation therapy are related to cardiovascular conditions associated with blood clots. These indications include stroke prevention in atrial fibrillation patients, venous thrombosis, and acute coronary syndrome. The annual world market for such drugs is predicted to reach $24 billion per year, having grown from $6.5 billion in 2001.

Verseon has designed a class of compounds that inhibit thrombin through a novel mechanism of action. These compounds present a unique coagulation and dose-response profile in functional assays in contrast to more conventional therapies, including those currently on the market. As such, Verseon's compounds constitute a new class of anticoagulant therapy with novel pharmacology.

In addition to being highly selective and very potent in both in vitro and functional assays, many of Verseon's drug candidates have favorable pharmacokinetic and toxicity profiles. Many of these drug candidates have successfully demonstrated pre-clinical proof-of-concept in in vivo efficacy studies with results that compare favorably to existing anticoagulants. Finally, Verseon's candidates have demonstrated significantly reduced bleeding risk compared with conventional anticoagulants when tested in in vivo pre-clinical studies.

Our current drug portfolio spans four separate therapeutic areas, all with unmet (or poorly met) medical needs


Current Pipeline

First-in-class oral anticoagulants for cardiovascular indications

Kallikrein inhibitors for the treatment of diabetic macular edema

Kallikrein inhibitors for the treatment of hereditary angioedema

Novel angiogenesis inhibitors for the treatment of solid tumors